Skip to main content
SpringerLink
Log in

Monoamine Oxidase Inhibitors as Antidepressants

  • Chapter
Psychotropic Agents

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 55 / 1))

Abstract

The history of monoamine oxidase inhibitor (MAOI) use in psychiatry is a curious one and far from complete. The inspiration for our own use derived from the work of Chessin et al. (1956) who found that “marsalinizing” (treating with Marsilid, i.e., iproniazid) an animal before administering reserpine produced a paradoxical effect1. The animal rather than becoming sedated became hyperalert and active. Scott described these findings during a visit to Warner Laboratories as part of a discussion which dealt with the mode of action of reserpine. The possibility of using this combination to activate retarded schizophrenic patients and to treat depression suggested itself.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ananth, J., Luchins, D.: A review of combined tricyclic and MAOI therapy. Compr. Psychiatry 18, 221–230 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Asatoor, A.M., Levi, A.J., Milne, M.D.: Tranylcypromine and cheese. Lancet 2, 733–734 (1963)

    Article  PubMed  CAS  Google Scholar 

  • Axelrod, J.: O-methylation of epinephrine and other catechols in vitro and in vivo. Science 126, 400 (1957)

    Article  PubMed  CAS  Google Scholar 

  • Ayd, F.J.: A preliminary report on marsilid. Am. J. Psychiatry 114, 459 (1957)

    PubMed  Google Scholar 

  • Bailey, S.D., Bucci, L., Gosline, E., Kline, N.S., Park, I.H., Rochlin, D., Saunders, J.C., Vaisberg, M.: Comparison of iproniazid with other amine oxidase inhibitors, including W-1544, JB-516, R04-1018, and R05-0700. Ann. N.Y. Acad. Sci. 80, 652–668 (1959)

    Article  PubMed  CAS  Google Scholar 

  • Baldessarini, R.J.: Mood drugs. In: Disease-A-Month. Dowling, H.F. (ed.), Vol. 24, 2., Chicago: Year Book Medical Publishers 1977

    Google Scholar 

  • Berger, P.A., Barchas, J.D.: Monoamine oxidase inhibitors. In: Psychotherapeutic drugs. Usdin, E., Forrest, I. (eds.). New York: Dekker 1977

    Google Scholar 

  • Biel, J.H., Bopp, B.: Monoamine oxidase inhibitor antidepressants. In: Psychopharmacological agents. Gordon, M. (ed.), pp. 302–309. New York: Academic Press 1974

    Google Scholar 

  • Birkmayer, W., Yahr, M. (eds.): Deprenyl, an inhibitor of MAO-type B in the treatment of Parkinsonism. J. Neural. Transm. 43, 3–4 (1978)

    Google Scholar 

  • Blackwell, B., Marley, E., Ryle, A.: Hypertensive crisis associated with monoamine-oxidase inhibitors. Lancet 1, 722–723 (1964)

    Article  PubMed  CAS  Google Scholar 

  • Brodie, B.B., Pletscher, A., Shore, P.A.: Possible role of serotonin in brain function and in reserpine action. J. Pharmacol. Exp. Ther. 116, 9 (1956)

    Google Scholar 

  • Bunney, W.E., Davis, J.M.: Norepinephrine in depressive reactions. A review. Arch. Gen. Psychiatry 13, 483–494 (1965)

    CAS  Google Scholar 

  • Burn, J.H., Philpot, F.J., Trendelenburg, U.: Effect of denervation on enzymes in iris and blood vessels. Br. J. Pharmacol. 9, 423–428 (1954)

    CAS  Google Scholar 

  • Chessin, M., Dubnick, B., Kramer, E.R., Scott, C.C.: Modifications of pharmacology of reser-pine and serotonin by iproniazid. Fed. Proc. 15, 409 (1956)

    Google Scholar 

  • Cooper, A.J., Ashcroft, G.: Potentiation of insulin hypoglycaemia by MAOI antidepressant drugs. Lancet 1, 407–409 (1966)

    Article  PubMed  CAS  Google Scholar 

  • Crane, G.E.: Further studies on iproniazid phosphate. Isonicotinil-isopropylhydrazine phosphate Marsilid. J. Nerv. Ment. Dis. 124, 322–331 (1956)

    Article  PubMed  CAS  Google Scholar 

  • Crane, G.E.: The psychiatric side-effects of iproniazid. Am. J. Psychiatry 112, 494–501 (1956)

    PubMed  CAS  Google Scholar 

  • Davidson, J., McCleod, M.N., Blum, M.R.: Acetylation phenotype, platelet monoamine oxidase inhibition, and the effectiveness of phenelzine in depression. Am. J. Psychiatry 135, 467–469 (1978)

    PubMed  CAS  Google Scholar 

  • Dunleavy, D.L.F., Oswald, I.: Phenelzine, mood response and sleep. Arch. Gen. Psychiatry 28, 353–356 (1973)

    PubMed  CAS  Google Scholar 

  • Escobar, J.I., Schiele, B.C., Zimmermann, R.: The tranylcypromine isomers: A controlled clinical trial. Am. J. Psychiatry 131, 1025–1026 (1974)

    PubMed  CAS  Google Scholar 

  • Evans, D.A.P., Manley, K.A., McKusick, V.A.: Genetic control of isoniazid metabolism in man. Br. Med. J. 2, 485–491 (1960)

    Article  PubMed  CAS  Google Scholar 

  • Evans, D.A.P., Davison, K., Pratt, R.T.C.: The influence of acetylator phenotype on the effects of treating depression with phenelzine. Clin. Pharmacol. Ther. 6, 430–435 (1965)

    PubMed  CAS  Google Scholar 

  • Fisher, M.M., Mammlok, E.R., Tendlau, A., Tebrock, H.E., Drumm, A.E., Spiegelman, A.: Isonicotinic acid hydrazide and its derivatives in tuberculosis: An evaluation of the side-effects in relation to peripheral circulation; preliminary report. 52, 1519–1527 (1952)

    Google Scholar 

  • Fowler, C.J., Callingham, B.A., Mantle, T.J., Tipton, K.F.: Monoamine oxidase A and B: A useful concept? Biochem. Pharmacol. 27, 97–101 (1978)

    Article  CAS  Google Scholar 

  • Franzen, F., Eysell, K. (eds.): Biologically active amines found in man. Oxford: Pergamon Press 1969

    Google Scholar 

  • Friend, D.G., Zileli, M.S., Hamlin, J.T., Reutter, F.W.: The effect of iproniazid on the inacti-vation of norepinephrine in the human. J. Clin. Exp. Psychopathol. 19, 61–71 (1958)

    PubMed  CAS  Google Scholar 

  • Fuller, R.W.: Selective inhibition of monoamine oxidate. Adv. Biochem. Psychopharm. 5, 339–354 (1972)

    CAS  Google Scholar 

  • Fuller, R.W.: Selectivity among monoamine oxidase inhibitors and its possible importance for development of antidepressant drugs. Prog. Neuropsychopharmacol. 2, 303–311 (1978)

    Article  CAS  Google Scholar 

  • Fuller, R.W., Roush, B.W.: Procaine hydrochloride as a monoamine oxidase inhibitor: Implications for geriatric therapy. J. Am. Geriatr. Soc. 25, 90–93 (1977)

    PubMed  CAS  Google Scholar 

  • Gaddum, J.H., Kwiatkowski, H.: The action of ephedrine. J. Physiol. (Lond.) 94, 87–100 (1938)

    PubMed  CAS  Google Scholar 

  • Goodman, L.S., Gilman, A.: The pharmacological basis of therapeutics. 2nd ed., p. 517. New York: Macmillan 1965

    Google Scholar 

  • Hendley, E.D., Snyder, S.H.: Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy. Nature 220, 1330–1331 (1968)

    Article  PubMed  CAS  Google Scholar 

  • Hodge, J.V., Nye, E.R., Emerson, G.W.: Monoamine-oxidase inhibitors, broad beans, and hypertension. Lancet 1, 1108 (1964)

    Article  PubMed  CAS  Google Scholar 

  • Horwitz, D., Goldberg, L.I., Sjoerdsma, A.: Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J. Lab. Clin. Med. 56, 747–753 (1960)

    PubMed  CAS  Google Scholar 

  • Horwitz, D., Lovenberg, W., Engelman, K., Sjoerdsma, A.: Monoamine oxidase inhibitors, tyramine, and cheese. J. Am. Med. Assoc. 188, 1108 (1964)

    CAS  Google Scholar 

  • Houslay, M.D., Garrett, N.J., Tipton, K.F.: Mixed substrate experiments with human brain monoamine oxidase. Biochem. Pharmacol. 23, 1937–1944 (1974)

    CAS  Google Scholar 

  • Houslay, M.D., Tipton, K.F., Youdim, M.B.H.: Minireview Multiple forms of monoamine oxidase: Fact and artefact. Life Sci. 19, 467–478 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Jarvik, M.: Drugs used in the treatment of psychiatric disorders. In: The pharmacological basis of therapeutics. 5 th ed. Goodman, L.S., Gilman, A. (eds.), pp. 151–203. New York: MacMillan 1970

    Google Scholar 

  • Johnston, J.P.: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1285–1297 (1968)

    Article  PubMed  CAS  Google Scholar 

  • Johnstone, E.C., Marsh, W.: Acetylator status and response to phenelzine in depressed patients. Lancet 1, 567–570 (1973)

    Article  PubMed  CAS  Google Scholar 

  • Kamman, G.R., Freeman, J.G., Lucero, R.J.: The effect of l-isonicotynil-2-isopropyl hydrazine (IIH) on the behavior of long-term mental patients. J. Nerv. Ment. Dis. 118, 391–407 (1953)

    Article  PubMed  CAS  Google Scholar 

  • Kiloh, L.G., Child, J.P., Latner, G.: A controlled trial of iproniazid in the treatment of endogenous depression. J. Ment. Sci. 106, 1139–1144 (1960)

    PubMed  CAS  Google Scholar 

  • Kline, N.S.: Present status of psychopharmacological Research: Includes Loomer, H., Saunders, J.C., Kline, N.S.: Iproniazid, an amine oxidase inhibitor, as an example of a psychic energizer. Hearings before the subcommittee of the Committee on Appropriations, United States Senate, 85th Congress, 1st Session on H.R. 6287, pp. 1372–1390, May 9, 1957. Washington, D.C.: U.S. Government Printing Office 1957

    Google Scholar 

  • Kline, N.S.: Quoted in: Berger, P.A., Barchas, J.D. In: Psychotherapeutic drugs. Usdin, E., Forrest, I. (eds.), p. 1175. New York: Dekker 1977

    Google Scholar 

  • Kline, N.S., Sacks, W.: Relief of depression within one day using an M.A.O. inhibitor and intravenous 5-HTP. Am. J. Psychiatry 120, 274–275 (1963)

    PubMed  CAS  Google Scholar 

  • Kline, N.S., Sacks, W.: Treatment of depression with an MAO inhibitor followed by 5-HTP — an unfinished research project. Presented at Symposium on Biogenic Amines and Affective Disorders. London. Jan. 18–21, 1979

    Google Scholar 

  • Kline, N.S., Alexander, S.F., Chamberlain, A.: In: Psychotropic drugs. Manual for emergency management overdosage. New Jersey: Medical Economics Company 1974

    Google Scholar 

  • Kline, N.S., Sacks, W., Simpson, G.M.: Further studies on: One day treatment of depression with 5-HTP. Am. J. Psychiatry 121, 379–381 (1964)

    PubMed  CAS  Google Scholar 

  • Kopin, I.J., Axelrod, J.: The role of monoamine oxidase in the release and metabolism of norepinephrine. Ann. N.Y. Acad. Sci. 107, 848 (1963)

    Article  PubMed  CAS  Google Scholar 

  • Krikler, D.M., Lewis, B.: Dangers of natural foodstuffs. Lancet 1, 1166 (1965)

    Article  Google Scholar 

  • Lader, M.: Antianxiety drugs: Clinical pharmacology and therapeutic use. Drugs 12, 362–373 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Leonard, B.E.: Some effects of mianserin on monoamine metabolism in the rat brain. Br. J. Clin. Pharmacol. 5, 11S–12S (1978)

    PubMed  Google Scholar 

  • Loomer, H.P., Saunders, J.C., Kline, N.S.: A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr. Res. Rep. 8, 129–141 (1958)

    Google Scholar 

  • Maclean, R., Nicholson, W.J., Pare, C.M.B., Stacey, R.S.: Effect of monoamine-oxidase inhibitors on the concentrations of 5-hydroxytryptamine in the human brain. Lancet 2, 205–208 (1965)

    Article  Google Scholar 

  • Marley, E.: Monoamine oxidase inhibitors. In: Drug interactions. Grahame-Smith, D.G. (ed.), pp. 178–194. Baltimore: University Park Press 1977

    Google Scholar 

  • Marshall, E.F., Mountjoy, C.O., Campbell, I.C., Garside, R.F., Leitch, I.M., Roth, M.: The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial. Br. J. Clin. Pharmacol. 6, 247–254 (1978)

    PubMed  CAS  Google Scholar 

  • Mielke, D.H.: Adverse reactions of thymoleptics. In: Depression: Behavioral, biochemical, diagnostic and treatment concepts. Gallant, D.M., Simpson, G.M. (eds.), pp. 273–308. Stuttgart: Spectrum Publications 1976

    Google Scholar 

  • Morris, J.B., Beck, A.T.: The efficacy of antidepressant drugs. A review of research (1958 to 1972). Arch. Gen. Psychiatry 30, 667–674 (1974)

    PubMed  CAS  Google Scholar 

  • Murphy, D.L.: The behavioral toxicity of monoamine oxidase-inhibiting antidepressants. Adv. Pharmacol. Chemother. 14, 71–105 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Murphy, D.L., Donnelly, C.H.: Monoamine oxidase in man: enzyme characteristics in platelets, and other human tissue. In: Neuropsychopharmacology of monoamines and their regulatory enzymes. Usdin, E. (ed.), pp. 71–85. New York: Raven Press 1974

    Google Scholar 

  • Murphy, D.L., Belmaker, R., Wyatt, R.J.: Monoamine oxidase in schizophrenia and other behavioral disorders. J. Psychiatr. Res. 11, 221–247 (1974)

    Article  PubMed  CAS  Google Scholar 

  • Neff, N.H., Yang, H.-Y.T.: Life Sci. 14, 2061–2074 (1974)

    Article  PubMed  CAS  Google Scholar 

  • Nelson, S.D., Mitchell, J.R., Timbrell, J.A., et al: Isoniazid and iproniazid: Activation of metabolites to toxic intermediates in man and rat. Science 193, 901–903 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Nies, A., Robinson, D.S., Lamborn, K.R., Lampert, R.P.: Genetic control of platelet and plasma monoamine oxidase activity. Arch. Gen. Psychiatry 28, 834–838 (1973)

    PubMed  CAS  Google Scholar 

  • Nies, A., Robinson, D.S., Harris, L.S., Lamborn, K.R.: Comparison of monoamine oxidase substrate activity in twins, schizophrenics, depressives, and controls. In: Advances in bio-chem. psychopharmacol. Neuropsychopharmacology of monoamine and their regulatory enzymes. Usdin, E. (ed.). New York: Raven Press 1974

    Google Scholar 

  • Ostow, M., Kline, N.S.: The psychic action of reserpine and chlorpromazine. In: Psychophar-macology frontiers. Kline, N.S. (ed.), Appendix, pp. 481–513. Boston, Mass.: Little, Brown & Co. 1959

    Google Scholar 

  • Paykel, E.S.: Classification of depressed patients: A cluster analysis derived grouping. Br. J. Psychiatry 118, 275–288 (1971)

    Article  PubMed  CAS  Google Scholar 

  • Pletscher, A., Shore, P.A., Brodie, B.B.: Serotonin as a mediator of reserpine action in brain. J. Pharmacol. Exp. Ther. 116, 84–89 (1956)

    PubMed  CAS  Google Scholar 

  • Raskin, A.: Adverse reactions to phenelzine: Results of a nine-hospital depression study. J. Clin. Pharmacol. 12, 22–25 (1972)

    CAS  Google Scholar 

  • Robinson, D.S., Lovenberg, W., Keiser, H., Sjoerdsma, A.: Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem. Pharmacol. 17, 109–119(1968)

    Article  PubMed  CAS  Google Scholar 

  • Robinson, D.S., Nies, A., Ravaris, C.L., Ives, J.O., Bartlett, D.: Clinical psychopharmacology of phenelzine: MAO activity and clinical response. In: Psychopharmacology: A generation of progress. Lipton, M.A., DiMascio, A., Killam, K.F. (eds.). New York: Raven Press 1978

    Google Scholar 

  • Rosloff, B.N., Davis, J.M.: Effect of iprindole on norepinephrine turnover and transport. Psychopharmacologia (Berl.) 40, 53–64 (1974)

    Article  CAS  Google Scholar 

  • Saunders, J.C., Radinger, N., Rochlin, D., Kline, N.S.: Treatment of depressed and regressed patients with iproniazid and reserpine. Dis. Nerv. Syst. 20, 1–8 (1959)

    Google Scholar 

  • Schiele, B.C.: The parnate specific patient. Minn. Med. 48, 355–357 (1965)

    Google Scholar 

  • Schildkraut, J.J.: The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am. J. Psychiatry 122, 509–522 (1965)

    PubMed  CAS  Google Scholar 

  • Schuckit, M., Robins, E., Feighner, J.: Tricyclic antidepressants and monoamine oxidase inhibitors: Combination therapy in the treatment of depression. Arch. Gen. Psychiatry 24, 509–514 (1971)

    PubMed  CAS  Google Scholar 

  • Selikoff, I.J., Robitzvek, E.H., Ornstein, G.G.: Toxicity of hydrazine derivatives of isonicotinic acid in the chemotherapy of human tuberculosis. Q. Bull. Sea View Hosp. 13, 17–26 (1952)

    CAS  Google Scholar 

  • Shaw, D.M.: The practical management of affective disorders. Br. J. Psychiatry 130, 432–451 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Shopsin, B., Kline, N.S.: Monoamine oxidase inhibitors: Potential for drug abuse. Biol. Psychiatry 11, 451–456 (1976)

    CAS  Google Scholar 

  • Sjoqvist, F.: SPIIn: Monoamine oxidase inhibitors: Relationship between pharmacological and clinical effects. Cheymol, J., Boissier, J.R., Vol. 10. New York: Pergamon Press 1968

    Google Scholar 

  • Smith, J.A.: The use of the isopropyl derivative of isonicotinylhydrazine (marsilid) in the treatment of mental disease; A preliminary report. Am. Practitioner 4, 519–520 (1953)

    PubMed  CAS  Google Scholar 

  • Spector, S., Hirsch, C.W., Brodie, B.B.: Association of behavioral effects of pargyline, a non-hydrazide monoamine oxidase inhibitor with increase in brain norepinephrine. Int. J. Neuropharmacol. 2, 81–93 (1963)

    Article  CAS  Google Scholar 

  • Spiker, D.G., Pugh, D.D.: Combining tricyclic and monoamine oxidase inhibitor antidepressants. Arch. Gen. Psychiatry 33, 828–830 (1976)

    PubMed  CAS  Google Scholar 

  • Tyrer, P., Candy, J., Kelly, D.: Phenelzine in phobia anxiety: A controlled trial. Psychol. Med. 3, 120–124 (1973)

    Article  PubMed  CAS  Google Scholar 

  • Usdin, E. (ed.): Neuropsychopharmacology of monoamines and their regulatory enzymes. Advances in biochemical psychopharmacology, Vol. 12. New York: Raven Press 1974

    Google Scholar 

  • Von Bruecke, F., Hornykiewicz, O., Sigg, E.B.: Monoamine oxidase inhibitors. In: The pharmacology of psychotherapeutic drugs. pp. 78–102. Berlin, Heidelberg, New York: Springer 1969

    Google Scholar 

  • West, E.D., Dally, P.J.: Effects of iproniazid in depressive syndromes. Br. Med. J. 1, 1491–1494 (1959)

    Article  PubMed  CAS  Google Scholar 

  • Yang, H.-Y.T., Neff, N.H.: B-phenylethylamine: A specific substrate for type B monoamine oxidase of brain. J. Pharmacol. Exp. Ther. 187, 365–371 (1973)

    PubMed  CAS  Google Scholar 

  • Youdim, M.B.: Multiple forms of mitochondrial monoamine oxidase. Br. Med. Bull. 29, 120–122 (1973)

    PubMed  CAS  Google Scholar 

  • Zeller, E.A., Barsky, J.: In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropyl hydrazine. Proc. Soc. Exp. Biol. Med. 81, 459–461 (1952)

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. N. S. Kline
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. B. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Pharmakologie, Bayer AG, Aprather Weg 18a, D-5600, Wuppertal 1, Germany

    F. Hoffmeister

  2. Institut für Arzneimittel des Bundesgesundheitsamtes, StauffenbergstraÜe 13, D-100, Berlin 30, Germany

    G. Stille

Rights and permissions

Reprints and permissions

Copyright information

© 1980 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kline, N.S., Cooper, T.B. (1980). Monoamine Oxidase Inhibitors as Antidepressants. In: Hoffmeister, F., Stille, G. (eds) Psychotropic Agents. Handbook of Experimental Pharmacology, vol 55 / 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67538-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-67538-6_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-67540-9

  • Online ISBN: 978-3-642-67538-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation